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Tetranectin is a plasminogen kringle 4 domain-binding protein present in plasma and various tissue locations. Decreased plasma
tetranectin or increased tetranectin in stroma of cancers correlates with cancer progression and adverse prognosis. A possible mech-
anism through which tetranectin could influence cancer progression is by altering activities of plasminogen or the plasminogen
fragment, angiostatin. Tetranectin was found to bind to the kringle 1-4 form of angiostatin (ASTK1-4). In addition, tetranectin in-
hibited binding of plasminogen or ASTK1-4 to extracellular matrix (ECM) deposited by endothelial cells. Finally, tetranectin partially
counteracted the ability of ASTK1-4 to inhibit proliferation of endothelial cells. This latter effect of tetranectin was specific for ASTK1-4
since it did not counteract the antiproliferative activities of the kringle 1-3 form of angiostatin (ASTK1-3) or endostatin. These findings
suggest that tetranectin may modulate angiogenesis through interactions with AST.
INTRODUCTION
Tetranectin (TN) plays a role in skeletal formation
during development since targeted deletion of the pro-
tein results in spinal deformity [1]. The function(s) of
tetranectin in postnatal life have not been elucidated al-
though there is evidence for roles in tissue remodeling, co-
agulation, and cancer. Tetranectin was originally isolated
as a plasminogen-binding protein that can enhance plas-
minogen activation in the presence of tissue plasminogen
activator [2]. Tetranectin binds to plasminogen through
a calcium-sensitive interaction of its C-terminal domain
with kringle 4 domain of plasminogen [3, 4]. Tetranectin
also has a distinct binding site in its N-terminus that
mediates binding to complex sulfated carbohydrates (eg,
heparin) [5]. The N-terminus of tetranectin could, there-
fore, mediate binding to extracellular matrix components.
Plasma levels of tetranectin are approximately 100 nM
in healthly adults [6]. However, these levels decline in
patients with cancer and rheumatoid arthritis [6, 7, 8].
Tetranectin is also found in a mobilizable set of gran-
ules in neutrophils [9], in monocytes [10] and platelets
[7], and in various tissue locations like cartilage and the
extracellular matrix (ECM) of developing or regenerat-
ing muscle [11, 12, 13]. Tetranectin is implicated in the
pathogenesis of cancer since decreased plasma levels of
tetranectin correlate with cancer progression [6, 14]. In
the case of ovarian cancer, decreased plasma levels of
tetranectin were a stronger predictor of adverse prognosis
than cancer stage [15]. Furthermore, tetranectin is present
in the stroma of various cancers (eg, breast, ovary, colon),
whereas it is not present in normal tissue from which the
cancers arose [16, 17]. Positive staining for tetranectin in
cancer stroma has also been strongly correlated with can-
cer progression [15].
The mechanisms through which tetranectin may par-
ticipate in cancer progression have not been elucidated.
Tetranectin colocalizes with plasminogen in the invasive
front of melanoma lesions [18], although how tetranectin
affects binding or local activation of plasminogen in can-
cer stroma has not been determined. This paper explores
the hypothesis that tetranectin may interact with angio-
statin. Angiostatin is formed in cancer tissues by pro-
teolytic degradation of plasminogen. The predominant
form of angiostatin produced in cancer tissues is ASTK1-4
[19, 20, 21]. ASTK1-4 inhibits cancer progression and
metastasis by inhibiting cancer-related angiogenesis. We
demonstrate that tetranectin binds to ASTK1-4 and re-
duces its ability to bind to ECM of endothelial cells or to
inhibit endothelial cell growth.
METHODS
Reagents
Human plasminogen and an antibody directed against
K1-3 domain of plasminogen were purchased from
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Enzyme Research Labs (South Bend, Ind). Rabbit anti-
human tetranectin (with or without horseradish peroxi-
dase attached) was obtained from DAKO Corp (Carpin-
teria, Calif).
Recombinant angiostatins and endostatin
Recombinant human angiostatins containing kringle
domains 1-3 and 1-4 (ASTK1-3 and ASTK1-4), and recom-
binant human endostatin were graciously provided byDrs
Nicolas MacDonald and Kim Lee Sim (EntreMed, Inc,
Rockville, Md). ASTK1-4 was produced in Chinese hamster
ovary cells and purified as described in [22]. Endostatin
and ASTK1-3 were produced in Pichia pastoris [23, 24]. Na-
tive ASTK1-4 derived from human plasma was purchased
from Angiogenesis Research Industries (Chicago, Ill). The
recombinant and native angiostatins had similar endothe-
lial cell growth inhibitory properties (data not shown).
The native preparation was used in the endothelial growth
inhibition assays (see below).
Enzyme-linked immunoabsorbent assay (ELISA)
for binding of angiostatin or plasminogen
to tetranectin
Binding of angiostatin or plasminogen to tetranectin
was assessed by coating plates initially with wild type or
mutant forms of tetranectin. Tetranectin was diluted to
a final concentration of 6.8 µg/mL (100 nM) in coating
buffer (bicarbonate buffer at pH 9.6), added to 96-well
microtitre plates (Costar, Corning Inc, Corning, NY), and
incubated overnight at 4◦C. The wells were washed and
then incubated with either plasminogen (22.5 µg/mL) or
angiostatin (50 µg/mL) at room temperature for 1 hour.
Bound plasminogen or angiostatin was detected by addi-
tion of a 1 : 1000 dilution of antibody directed against
the kringle 1-3 domain of plasminogen (Enzyme Research
Laboratories, South Bend, Ind) for 1 hour at room tem-
perature. Preliminary studies demonstrated that this anti-
body recognized angiostatin and plasminogen to a sim-
ilar extent. A secondary antibody (HRP-labeled donkey
anti-mouse IgG; Jackson Research Labs, West Grove, Pa)
was then added at 1 : 40 000 dilution for 1 hour at room
temperature. Binding was detected using a TMB peroxi-
dase EIA substrate kit (BioRad, Hercules, Calif) and 1N
H2SO4. OD 450 readings were measured using a Titertek
Multiscan reader. In all experiments, background binding
of plasminogen and angiostatin was tested by including
additional wells coated with 2.5% BSA only. Note that ini-
tial experiments were attempted in which angiostatin or
plasminogen was coated onto ELISA plates followed by
addition of tetranectin. However, it was found that back-
ground binding of tetranectin to BSA-coated plates was
too high to reliably assess binding by this method.
Recombinant tetranectins
Recombinant wild-type human tetranectin was pro-
duced in E coli, refolded and purified as described in [10].
Mutant tetranectins were generated by site-directed mu-
tagenesis as described in [3, 4].
Assay of binding of plasminogen or angiostatin
to ECMof endothelial cells
ECM was prepared from human umbilical vein en-
dothelial cells (HUVECs) grown for 2 days postconfluence
as described in [25]. HUVECs were obtained from Clo-
netics Products, a division of BioWhittaker (San Diego,
Calif) and cultured as outlined in the manufacturer’s in-
structions. The subendothelial matrix was recovered by
removing cells with 0.5% Triton X-100 in PBS (pH 7.4)
followed by incubation with 25mM NH4OH to remove
cytoskeletal elements, and then washed with PBS supple-
mented with 0.05% tween-20. The adherent ECM was
incubated with 1% BSA in PBS to saturate nonspecific
protein binding sites. AST (at 0.5, 0.25, and 0.125 µM)
was preincubated with TN (at 100 nM) for 30 minutes at
37◦C and then added to designated wells of 96-well plate.
Bound AST was detected as described above.
Assay of endothelial cell proliferation
HUVECs were seeded overnight in minimum essen-
tial medium containing 2.5% fetal bovine serum (FBS)
in a 96-well plate (5000 cells/well) at 37◦C. The follow-
ing day, fresh medium supplemented with basic fibrob-
last growth factor (bFGF; 10 ng/mL) was added. In addi-
tion, tetranectin, angiostatin, or endostatin or combina-
tions of these proteins were added to triplicate wells. The
cells were incubated for 72 hours by replenishing fresh
medium and test substances (bFGF, angiostatin, endo-
statin, tetranectin) as indicated at 24 hours and 48 hours.
Cells were then harvested at 72 hours and counted by
hemocytometer.
RESULTS
Plasminogen and angiostatin bind to tetranectin
As expected, plasminogen bound to recombinant
wild-type tetranectin (Figure 1). Since the form of an-
giostatin composed of kringle domains 1-4 of plasmino-
gen (ASTK1-4) contains the kringle 4, we tested its bind-
ing to tetranectin in parallel. ASTK1-4 also bound sig-
nificantly to tetranectin (Figure 1). The mechanism of
binding of tetranectin to plasminogen has been de-
termined through the use of tetranectin mutants [3].
Binding is calcium-sensitive (ie, reduced by increas-
ing concentrations of calcium) and is mediated by C-
terminal domain of tetranectin. A mutant form of
tetranectin in which lysine 148 was replaced with ala-
nine (TNK148A) binds to plasminogen markedly less than
wild type tetranectin [4]. In contrast, substitution of
threonine 149 with tyrosine (TNT149Y) resulted in in-
creased binding to kringle 4 [4]. Plasminogen and ASTK1-4
bound significantly less to the TNK148A and significantly
more to TNT149Y than to wild type TN (Table 1 and
Figure 1).
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Figure 1. Binding of plasminogen or ASTK1-4 to tetranectin.
ELISA plates were coated with recombinant wild-type human
tetranectin (100 nM) or BSA, and then treated with plasmino-
gen (22.5 µg/mL) and ASTK1-4 (50 µg/mL). Results shown are
mean ± SEM of 5 experiments (each experiment done in trip-
licate). Binding of plasminogen and ASTK1-4 to tetranectin was
significantly greater than binding to BSA-coated plates (P < .01).
Binding of plasminogen to TN was significantly greater than
binding of ASTK1-4 (P < .05).
As shown in Figure 1, ASTK1-4 bound to wild-type
TN significantly less than plasminogen. However, binding
of ASTK1-4 to the TNT149Y form was equivalent to bind-
ing of plasminogen. Increased plasminogen and angio-
statin binding of TNT149Y could result from the greater
affinity of this mutant for kringle 4. TNT149Y is also dis-
tinguished from wild-type tetranectin in that it binds to
the kringle 2 domain of plasminogen [4], which could
be involved in binding to ASTK1-4. This is likely to be the
case since ASTK1-3 showed significant binding to TNY149A,
whereas binding of wild-type TN to ASTK1-3 was not sig-
nificantly greater than background binding to BSA (data
not shown). Nonetheless, binding of ASTK1-3 to TNT149Y
was markedly less than that of ASTK1-4 or plasminogen,
indicating that increased affinity of TNT149Y for kringle 4
accounts for most of the increased binding of this mutant
to ASTK1-4.
Angiostatin (ASTK1-4) binds to ECMof
endothelial cells and tetranectin
inhibits this binding
Our next goal was to determine if tetranectin alters
functional activities of angiostatin. Plasminogen binds to
ECMof endothelial cells [25, 26].Wewanted to determine
if angiostatin also binds to ECM of endothelial cells and to
determine the effect of tetranectin on this binding. ECM
of HUVECs was prepared as described in [25]. As shown
in Figure 2, plasminogen did bind to this matrix and this
binding was significantly inhibited by pre-incubation of
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Figure 2. Tetranectin reduces binding of plasminogen to ECM
deposited by endothelial cells. ECM of endothelial cells was pro-
duced as described in “methods,” and binding of plasminogen
was measured using ELISA. The effect of tetranectin (wild type)
on binding of plasminogen was assessed by preincubation of
plasminogen with tetranectin (100 nM) for 30 minutes at 37◦C,
followed by addition of these samples to wells coated with ECM.
Results shown are mean ± SEM of 4 experiments (each exper-
iment done in triplicate). Binding of plasminogen at 22.5 or
45 µg/mL was significantly reduced by tetranectin (P < .05; in-
dicated by ∗).
Table 1. Binding of plasminogen and angiostatin, contain-
ing kringles 1-4 or kringles 1-3 (ASTK1-4, ASTK1-3), to mu-
tant tetranectins. Binding of plasminogen, angiostatin K1-4
(ASTK1-4), or angiostatin K1-3 (ASTK1-3) to TN mutants was as-
sessed by ELISA as in Figure 1. Results shown are mean ± SEM
of 6 specific binding determinations. Binding of plasminogen or
AST to BSA was subtracted from results shown.
Protein added TNK148A TNT149Y
Plasminogen 0.02± 0.006 1.73± 0.14
ASTK1-4 0.06± 0.02 1.83± 0.21
ASTK1-3 0.02± 0.006 0.43± 0.05
plasminogen with a physiological concentration (100 nM)
of wild-type tetranectin. As shown in Figure 3, ASTK1-4
also bound to the ECM and binding was again signifi-
cantly reduced by tetranectin.
Tetranectinmodulates the ability of angiostatin
to inhibit endothelial cell proliferation
ASTK1-4 significantly inhibited the bFGF-stimulated
growth of HUVECs as expected (Figure 4). Tetranectin
alone did not significantly alter proliferation in the
presence (Figure 4) or absence (data not shown) of
bFGF. However, when HUVECs were treated with both
tetranectin and ASTK1-4, proliferation was significantly
greater than that with ASTK1-4 alone. Note that tetranectin
did not completely reverse the antiproliferative action of
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Figure 3. Tetranectin reduces binding of angiostatin to ECM.
Binding of angiostatin (ASTK1-4) to ECM of endothelial cells was
measured as in Figure 2. At all concentrations tested, binding of
ASTK1-4 was significantly reduced by tetranectin (P < .05; indi-
cated by ∗). Results shown are mean ± SEM of 4 experiments
(each experiment done in triplicate).
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Figure 4. Tetranectin counteracts angiostatin-induced inhibi-
tion of proliferation of endothelial cells. HUVECs were seeded
overnight in 96-well plates (5000 cells/well). The following day,
fresh medium supplemented with basic fibroblast growth factor
(bFGF; 10 ng/mL) was added.Where indicated, tetranectin (TN;
100 nM) and/or ASTK1-4 (200 nM) were added to triplicate wells.
Cell numbers were counted after 72 hours. ASTK1-4 significantly
reduced the number of cells obtained (P < .008; indicated by ∗).
There were, however, significantly more cells in cultures treated
with the combination of tetranectin and ASTK1-4 than in those
treated with ASTK1-4 alone (P < .039; indicated by #). Note that
cultures treated with AST and tetranectin still have less cells than
control cultures (P < .05).
ASTK1-4 since there were still significantly fewer cells in
cultures treated with the combination of tetranectin and
ASTK1-4 than in control cultures.
Table 2. Effect of tetranectin on endothelial cell proliferation
in presence of control buffer, ASTK1-3 or endostatin. Endothe-
lial cell cultures were incubated for 72 hours in presence of the
indicated concentrations of recombinant wild-type tetranectin,
ASTK1-3, or endostatin alone or combinations of ASTK1-3 or en-
dostatin with tetranectin (final concentration 150 nM). Results
represent mean± SD number of cells/mL (×1000) in 4–6 exper-
iments (each done in triplicate). All concentrations of ASTK1-3
or endostatin significantly decreased endothelial cells numbers
(P < .05) in presence or absence of tetranectin. Tetranectin alone
significantly (P < .01) increased the number of endothelial cells
compared with control buffer alone although it did not alter the
effects of any concentration of ASTK1-3 or endostatin.
Inhibitor added Control Tetranectin 150 nM
Control 43.4± 1.4 51± 2.9∗∗
ASTK1-3 10 nM 40.5± 1.9 37.6± 5.7
ASTK1-3 50 nM 33.2± 2.2 34.1± 4
ASTK1-3 1 µM 32.3± 1.6 27.7± 1.6
Endostatin 125 nM 32.3± 2 30.3± 2
Endostatin 250 nM 27.2± 1.9 23.1± 7
Endostatin 500 nM 25.1± 3.5 22± 3.9
In the experiments shown in Figure 4, there was
a trend (not statistically significant) toward increased
proliferation of endothelial cells in response to tetranectin
alone. It was possible, therefore, that the ability of
tetranectin to counteract the antiproliferative activity of
ASTK1-4 resulted from independent effects of tetranectin
on endothelial cell proliferation, rather than from its in-
teraction with ASTK1-4. To study this further, we tested the
activity of additional concentrations of tetranectin alone,
or tetranectin in combination with endostatin or ASTK1-3
(Table 2). In these experiments, 150 nM concentration of
tetranectin alone modestly but significantly increased en-
dothelial cell proliferation. However, a further increase of
the concentration of tetranectin to 375 nM resulted in loss
of this enhancing activity (ie, endothelial cell counts in
cultures treated with 375 nM tetranectin were 38±3×103
as compared to 43 ± 1.4 in control; n = 6; P < .06).
Both endostatin and ASTK1-3 inhibited the growth of en-
dothelial cells as expected (Table 2). However, tetranectin
(150 nM) did not lessen the antiproliferative effect of ei-
ther ASTK1-3 or endostatin. These results suggest that the
ability of tetranectin to counteract the antiproliferative ac-
tivity of ASTK1-4 is not the result of an independent effect
of tetranectin on the endothelial cells.
DISCUSSION
The important novel findings of this paper are that
tetranectin binds to ASTK1-4, inhibits binding of plas-
minogen and ASTK1-4 to ECM of endothelial cells, and
partially counteracts the effects of ASTK1-4 on endothelial
cell proliferation. The mechanism of binding of ASTK1-4
to tetranectin is similar to that of plasminogen based on
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studies using mutant forms of tetranectin with enhanced
or reduced ability to bind plasminogen (Table 1). These
results also indicate that interactions of ASTK1-4 with
tetranectin could be modulated through introduction of
discrete modifications of tetranectin’s binding site for
plasminogen.
It is of note that although tetranectin bound signif-
icantly to ASTK1-4, binding to ASTK1-4 was significantly
less than binding to plasminogen. This finding was un-
expected since ASTK1-4 contains the principal binding
site for tetranectin (ie, kringle 4). It may be that the
conformation of kringle 4 in ASTK1-4 differs sufficiently
from its conformation in plasminogen to affect binding of
tetranectin. This binding difference may be significant in
some physiological situations. However, the other results
presented in this paper indicate strongly that binding of
tetranectin to ASTK1-4 is sufficient to affect other activities
of ASTK1-4.
We demonstrate that ASTK1-4, like plasminogen, binds
to the ECM of endothelial cells. This finding is novel and
of interest since it could relate to localization of angio-
statin in vivo. Of more relevance to the aims of this pa-
per, we also found that tetranectin significantly reduced
binding of ASTK1-4 to ECMof endothelial cells. The ability
of tetranectin to inhibit binding of ASTK1-4 to ECM sug-
gests that it could promote angiogenesis in vivo.We there-
fore tested whether tetranectin affects the antiangiogenic
activity of ASTK1-4. Physiological concentrations of wild-
type tetranectin significantly counteracted the effect of
ASTK1-4 on endothelial cell proliferation. Tetranectin did
not have a similar interaction with ASTK1-3 or endostatin
(Table 2), indicating that its ability to counteract the an-
tiangiogenic effects of ASTK1-4 is dependent on binding to
the kringle 4 domain and not to some other direct inter-
action with endothelial cells. Tetranectin alone had a vari-
ably enhancing effect on endothelial cell growth at some
concentrations. However, this effect was not dose-related
and is unlikely to account for the ability of tetranectin to
counteract antiproliferative effects of ASTK1-4 based upon
results shown in Table 2.
As noted, extensive data derived from the study of
clinical samples suggests that increased tetranectin in
the stroma of cancer tissues is associated with an ad-
verse prognosis in various cancers. Our findings suggest
that tetranectin may promote tumor progression by fa-
voring angiogenesis. Cancer-associated angiogenesis has
been quantitated by enumeration of the density of mi-
crovessels in tumor stroma. Increased microvessel density
is associated with adverse prognosis in many cancers [27].
Future studies could address whether increased microves-
sel density is associated with stromal tetranectin reactiv-
ity. The ability of tetranectin to modify other functional
properties of angiostatin should also be examined. One
immediate implication of our findings is that ASTK1-4 and
ASTK1-3 may have different activities in vivo based on dif-
ferential binding to tetranectin. This might account for
the increased elimination half-life of ASTK1-4 compared
with ASTK1-3 in vivo, or the fact that a similar inhibition
of cancer metastases was obtained with lower effective in
vivo exposure to ASTK1-3 than ASTK1-4 [22].
Angiostatin may inhibit angiogenesis in inflammatory
states [28] or after vascular injury [29]. Recent studies
demonstrate that biologically active angiostatin is pro-
duced by neutrophils [30], and that angiostatin inhibits
neutrophil migration and inflammation-induced angio-
genesis [31]. Of interest, prior studies demonstrated that
tetranectin is contained in a subset of neutrophils, from
which it can be released after cell stimulation with var-
ious agonists [9]. Hence, interactions of tetranectin and
plasminogen or angiostatin may also be involved in in-
flammatory processes. Whereas angiostatin produced in
cancer tissues appears most often to be ASTK1-4 [19, 21],
neutrophils produce ASTK1-3 [30]. Therefore, the partici-
pation of tetranectin in angiogenesis may vary in different
physiological or pathological states depending on which
form of angiostatin is produced.
In summary, we demonstrate that tetranectin binds to
the form of angiostatin commonly produced in cancer tis-
sues, characterize themechanism of binding usingmutant
forms of tetranectin, and show that tetranectin inhibits
important functional properties of angiostatin. These
findings provide insight into the mechanisms through
which tetranectin participates in cancer progression. Fur-
thermore, these findings have implications for therapeutic
use of different forms of angiostatin.
ACKNOWLEDGMENT
This work was supported by NIH Grant HL69031
(KLH).
REFERENCES
[1] Iba K, Durkin ME, Johnsen L, et al. Mice with a tar-
geted deletion of the tetranectin gene exhibit a spinal
deformity.Mol Cell Biol. 2001;21(22):7817–7825.
[2] Clemmensen I, Petersen LC, Kluft C. Purification
and characterization of a novel, oligomeric, plas-
minogen kringle 4 binding protein from human
plasma: tetranectin. Eur J Biochem. 1986;156(2):
327–333.
[3] Graversen JH, Lorentsen RH, Jacobsen C, et al.
The plasminogen binding site of the C-type lectin
tetranectin is located in the carbohydrate recogni-
tion domain, and binding is sensitive to both cal-
cium and lysine. J Biol Chem. 1998;273(44):29241–
29246.
[4] Graversen JH, Jacobsen C, Sigurskjold BW, et al. Mu-
tational analysis of affinity and selectivity of kringle-
tetranectin interaction. Grafting novel kringle affin-
ity onto the tetranectin lectin scaffold. J Biol Chem.
2000;275(48):37390–37396.
[5] Lorentsen RH, Graversen JH, Caterer NR, Thogersen
HC, Etzerodt M. The heparin-binding site in
78 Tirsit Mogues et al 2004:2 (2004)
tetranectin is located in the N-terminal region and
binding does not involve the carbohydrate recogni-
tion domain. Biochem J. 2000;347 (pt 1) :83–87.
[6] Jensen BA, Clemmensen I. Plasma tetranectin is re-
duced in cancer and related to metastasia. Cancer.
1988;62(5):869–872.
[7] Christensen L. The distribution of fibronectin,
laminin and tetranectin in human breast cancer with
special attention to the extracellular matrix. APMIS
Suppl. 1992;26:1–39.
[8] Kamper EF, Kopeikina LT, Koutsoukos V, Stavridis
J. Plasma tetranectin levels and disease activity in
patients with rheumatoid arthritis. J Rheumatol.
1997;24(2):262–268.
[9] Borregaard N, Christensen L, BejerrumOW, Birgens
HS, Clemmensen I. Identification of a highly mo-
bilizable subset of human neutrophil intracellular
vesicles that contains tetranectin and latent alkaline
phosphatase. J Clin Invest. 1990;85(2):408–416.
[10] Nielsen H, Clemmensen I, Kharazmi A. Tetranectin:
a novel secretory protein from human monocytes.
Scand J Immunol. 1993;37(1):39–42.
[11] Wewer UM, Ibaraki K, Schjorring P, Durkin ME,
Young MF, Albrechtsen R. A potential role for
tetranectin in mineralization during osteogenesis. J
Cell Biol. 1994;127(6):1767–1775.
[12] Clemmensen I, Lund LR, Christensen L, Andreasen
PA. A tetranectin-related protein is produced and
deposited in extracellular matrix by human embry-
onal fibroblasts. Eur J Biochem. 1991;195(3):735–
741.
[13] Wewer UM, Iba K, Durkin ME, et al. Tetranectin is a
novel marker for myogenesis during embryonic de-
velopment, muscle regeneration, andmuscle cell dif-
ferentiation in vitro. Dev Biol. 1998;200(2):247–259.
[14] Hogdall CK, Christiansen M, Norgaard-Pedersen B,
Bentzen SM, Kronborg O, Clemmensen I. Plasma
tetranectin and colorectal cancer. Eur J Cancer.
1995;31A(6):888–894.
[15] Hogdall CK, Hogdall EV, Hording U, Clemmensen
I, Norgaard-Pedersen B, Toftager-Larsen K. Pre-
operative plasma tetranectin as a prognostic marker
in ovarian cancer patients. Scand J Clin Lab Invest.
1993;53(7):741–674.
[16] Wewer UM, Albrechtsen R. Tetranectin, a plasmino-
gen kringle 4-binding protein. Cloning and gene ex-
pression pattern in human colon cancer. Lab Invest.
1992;67(2):253–262.
[17] Christensen L, Clemmensen I. Differences in
tetranectin immunoreactivity between benign and
malignant breast tissue. Histochemistry. 1991;95(5):
427–433.
[18] De Vries TJ, De Wit PE, Clemmensen I, et al.
Tetranectin and plasmin/plasminogen are simi-
larly distributed at the invasive front of cutaneous
melanoma lesions. J Pathol. 1996;179(3):260–265.
[19] O’Reilly MS, Holmgren L, Shing Y, et al. Angiostatin:
a novel angiogenesis inhibitor that mediates the sup-
pression of metastases by a Lewis lung carcinoma.
Cell. 1994;79(2):315–328.
[20] Gately S, Twardowski P, Stack MS, et al. The mecha-
nism of cancer-mediated conversion of plasminogen
to the angiogenesis inhibitor angiostatin. Proc Natl
Acad Sci USA. 1997;94(20):10868–10872.
[21] Richardson M, Gunawan J, Hatton MW, Seidlitz E,
Hirte HW, Singh G. Malignant ascites fluid (MAF),
including ovarian-cancer-associated MAF, contains
angiostatin and other factor(s) which inhibit angio-
genesis. Gynecol Oncol. 2002;86(2):279–287.
[22] MacDonald NJ, Murad AC, Fogler WE, Lu Y, Sim
BK. The tumor-suppressing activity of angiostatin
protein resides within kringles 1 to 3. Biochem Bio-
phys Res Commun. 1999;264(2):469–477.
[23] Sim BK, O’Reilly MS, Liang H, et al. A recom-
binant human angiostatin protein inhibits experi-
mental primary and metastatic cancer. Cancer Res.
1997;57(7):1329–1334.
[24] Sim BK, Fogler WE, Zhou XH, et al. Zinc ligand-
disrupted recombinant human Endostatin: potent
inhibition of tumor growth, safety and pharmacoki-
netic profile. Angiogenesis. 1999;3(1):41–51.
[25] Knudsen BS, Silverstein RL, Leung LL, Harpel PC,
Nachman RL. Binding of plasminogen to extracellu-
lar matrix. J Biol Chem. 1986;261(23):10765–10771.
[26] Stack MS, Gately S, Bafetti LM, Enghild JJ, Soff GA.
Angiostatin inhibits endothelial and melanoma cel-
lular invasion by blocking matrix-enhanced plas-
minogen activation. Biochem J. 1999;340(pt 1):77–
84.
[27] Hlatky L, Hahnfeldt P, Folkman J. Clinical applica-
tion of antiangiogenic therapy: microvessel density,
what it does and doesn’t tell us. J Natl Cancer Inst.
2002;94(12):883–893.
[28] Hamacher J, Lucas R, Lijnen HR, et al. Tumor necro-
sis factor-alpha and angiostatin are mediators of en-
dothelial cytotoxicity in bronchoalveolar lavages of
patients with acute respiratory distress syndrome.
Am J Respir Crit Care Med. 2002;166(5):651–656.
[29] Matsunaga T, Weihrauch DW, Moniz MC, Tessmer
J, Warltier DC, Chilian WM. Angiostatin inhibits
coronary angiogenesis during impaired produc-
tion of nitric oxide. Circulation. 2002;105(18):2185–
2191.
[30] Scapini P, Nesi L, Morini M, et al. Generation of bi-
ologically active angiostatin kringle 1-3 by activated
human neutrophils. J Immunol. 2002;168(11):5798–
5804.
[31] Benelli R, Morini M, Carrozzino F, et al. Neutrophils
as a key cellular target for angiostatin: implications
for regulation of angiogenesis and inflammation.
FASEB J. 2002;16(2):267–269.
∗ Corresponding author.
E-mail: khartsho@bu.edu
Fax: +1 617 638 7530; Tel: +1 617 638 5638
